

Nomination committee's proposal to the annual general meeting 2013

The nomination committee of Swedish Orphan Biovitrum AB (publ), which consists of Bo Jesper Hansen (chairman of the Board of Directors), Petra Hedengran, chairman (Investor), Roger Johanson (Skandia Liv) and Åsa Nisell (Swedbank Robur Fonder) proposes:

- that Klaes Edhall from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting,
- that fees to be paid to the Board of Directors should total SEK 2,190,000, to be allocated with SEK 300,000 to each board member except for the chairman of the Board of Directors who shall not receive any fee for his board assignment, nor any fee for his committee work, that fees for work in the audit committee should be SEK 90,000 to the chairman and SEK 50,000 to each other member of such committee, that fees for work in the compensation & benefit committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee and that fees for work in the science committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee,
- that, in addition to the fees proposed above, for each meeting of the Board of Directors a fee of SEK 10,000 is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a fee of SEK 20,000 is paid to the members of the Board of Directors that reside outside Europe.
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice,
- that seven ordinary board members without deputies should be appointed,
- that one auditor without any deputy auditor should be appointed,
- that the board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell should be re-elected and that Bo Jesper Hansen should be re-elected chairman of the Board of Directors, and
- that PricewaterhouseCoopers AB be elected auditor of the company until the end of the annual general meeting 2014.

The nomination committee of Swedish Orphan Biovitrum AB (publ)
in March 2013